Detection of cardiac amyloidosis on routine bone scintigraphy: an important gatekeeper role for the nuclear medicine physician

• Published in: The international journal of cardiovascular imaging Vol. 40; no. 6; pp. 1183 - 1192
• Main Authors: Nebhwani, Mohit, Chaibekava, Karina, Achten, Anouk, Oerlemans, Marish I. F. J., Michels, Michelle, van der Meer, Peter, Nienhuis, Hans L. A., Weerts, Jerremy, van Empel, Vanessa, Rocca, Hans-Peter Brunner-La, Wijk, Sandra Sanders-van, van der Pol, Jochem, Knackstedt, Christian
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.06.2024; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Amyloid Neuropathies, Familial - complications; Amyloid Neuropathies, Familial - diagnostic imaging; Amyloidosis; Bone and Bones - diagnostic imaging; Cardiac Imaging; Cardiology; Cardiomyopathies - diagnostic imaging; Cardiomyopathies - physiopathology; Electronic health records; Electronic medical records; Evaluation; Female; Health care facilities; Humans; Hypertrophy; Imaging; Male; Medicine; Medicine & Public Health; Netherlands; Nuclear medicine; Original Paper; Patients; Predictive Value of Tests; Radiology; Radionuclide Imaging; Radiopharmaceuticals - administration & dosage; Retrospective Studies; Scintigraphy; Time Factors; Transthyretin; Netherlands; Bonescintigraphy; Tc-HDP; Amyloidosis; Echocardiography; Prevalence; Follow-up; 99mTc-HDP
• ISSN: 1875-8312; 1569-5794; 1875-8312; 1573-0743
• DOI: 10.1007/s10554-024-03085-z

Cardiac amyloidosis (CA)—mostly transthyretin-related (ATTR-CA)—has recently gained interest in cardiology. Bone scintigraphy (BS) is one of the main screening tools for ATTR-CA but also used for various other reasons. The objective was to evaluate whether all CA cases are detected and what happens during follow-up. All routine BS performed at the Maastricht University Medical Center (May 2012–August 2020) were screened for the presence of CA. Scans performed for suspected CA were excluded. A Perugini stage ≥1 was classified as positive necessitating further examination. The electronic medical record system was evaluated for any contact with cardiology or other specialists until 2021. Of the 2738 BS evaluated, 40 scans (1.46%; median age 73.5 [IQR: 65.8–79.5], 82.5% male) were positive (Perugini grade 1: 31/77.5%, grade 2: 6/15%, grade 3: 3/7.5%); the potential diagnosis ATTR-CA was not seen in 38 patients (95%) by the nuclear medicine specialist. During follow-up, 19 out of those 40 patients (47.5%) underwent cardiac evaluation without diagnosing CA. Available echocardiograms of patients with a positive BS showed left ventricular hypertrophy, a preserved ejection fraction, and diastolic dysfunction ≥2 in 9/47%, 10/53%, and 4/21% of patients, respectively. Additionally, 20 (50%) patients presented to at least one specialty with symptoms indicative of cardiac amyloidosis. The prevalence of a positive BS indicating potential CA in an unselected population is low but substantial. The majority was not detected which asks for better awareness for CA of all involved specialists to ensure appropriate treatment and follow-up. Graphical abstract